ATE522534T1 - Pyrrolopyrazin-kinasehemmer - Google Patents

Pyrrolopyrazin-kinasehemmer

Info

Publication number
ATE522534T1
ATE522534T1 AT09715292T AT09715292T ATE522534T1 AT E522534 T1 ATE522534 T1 AT E522534T1 AT 09715292 T AT09715292 T AT 09715292T AT 09715292 T AT09715292 T AT 09715292T AT E522534 T1 ATE522534 T1 AT E522534T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
pyrrolopyrazine
pyrrolopyrazine kinase
syk
immune
Prior art date
Application number
AT09715292T
Other languages
English (en)
Inventor
Joe Bamberg
Bois Daisy Du
Todd Elworthy
Robert HENDRICKS
Johannes Hermann
Alam Jahangir
Rama KONDRU
Remy Lemoine
Yan Lou
Timothy Owens
Jaehyeon Park
David Smith
Michael Soth
Hanbiao Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE522534T1 publication Critical patent/ATE522534T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT09715292T 2008-02-25 2009-02-16 Pyrrolopyrazin-kinasehemmer ATE522534T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3103508P 2008-02-25 2008-02-25
US20572909P 2009-01-22 2009-01-22
PCT/EP2009/051755 WO2009106441A1 (en) 2008-02-25 2009-02-16 Pyrrolopyrazine kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE522534T1 true ATE522534T1 (de) 2011-09-15

Family

ID=40513792

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09715292T ATE522534T1 (de) 2008-02-25 2009-02-16 Pyrrolopyrazin-kinasehemmer

Country Status (8)

Country Link
US (1) US8008298B2 (de)
EP (1) EP2245033B1 (de)
JP (1) JP5368484B2 (de)
CN (1) CN101952295B (de)
AT (1) ATE522534T1 (de)
CA (1) CA2713324A1 (de)
ES (1) ES2372908T3 (de)
WO (1) WO2009106441A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE517107T1 (de) * 2008-02-25 2011-08-15 Hoffmann La Roche Pyrrolopyrazinkinaseinhibitoren
MX2012002641A (es) 2009-09-10 2012-03-14 Hoffmann La Roche Inhibidores de cinasa janus (jak).
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8481541B2 (en) * 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
MX2012013194A (es) 2010-05-20 2013-01-22 Hoffmann La Roche Derivados pirrolopirazinas como inhibidores de cinasas tirocina-cinasa del baso (syk) y cinasa de janus (jak).
EP2571880A1 (de) * 2010-05-20 2013-03-27 F.Hoffmann-La Roche Ag Pyrrolo [2, 3 - b]pyrazin - 7 - carboxamidderivate und ihre verwendung als jak- und syk-hemmer
EP2489663A1 (de) 2011-02-16 2012-08-22 Almirall, S.A. Verbindungen als Syk-Kinasehemmer
MX2013013331A (es) 2011-05-17 2014-10-17 Principia Biopharma Inc Derivados de azaindol como inhibidores de tirosina-cinasas.
WO2013030138A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
EP2773645A1 (de) 2011-11-01 2014-09-10 F.Hoffmann-La Roche Ag Imidazopyridazinverbindungen
KR20140108594A (ko) 2012-01-10 2014-09-11 에프. 호프만-라 로슈 아게 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도
AR089698A1 (es) * 2012-01-13 2014-09-10 Novartis Ag Compuestos heterociclicos antagonistas del receptor ip
US20170100396A1 (en) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza
EP4298908A3 (de) 2017-03-31 2024-03-20 Bayer Animal Health GmbH Trizyklische carboxamide zur bekämpfung von arthropoden
KR20220118525A (ko) 2019-12-20 2022-08-25 화이자 인코포레이티드 벤즈이미다졸 유도체
CN113984726B (zh) * 2021-10-20 2024-02-02 上海大学 一种氨基苯硼酸功能化磁珠/乙二醛修饰dna检测汞离子的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203895A3 (en) * 1999-12-24 2004-09-28 Aventis Pharma Ltd West Mallin Substituted azaindoles and pharmaceutical compositions containing them and their use
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
KR20040111445A (ko) * 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
JP5138938B2 (ja) * 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ｒｅｔ調節剤の開発のための化合物および方法
US7452993B2 (en) * 2004-07-27 2008-11-18 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
AU2005309566A1 (en) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or Rho kinase
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
WO2007015866A2 (en) * 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
RU2503676C2 (ru) * 2008-02-25 2014-01-10 Ф.Хоффманн-Ля Рош Аг Пирролопиразиновые ингибиторы киназы

Also Published As

Publication number Publication date
EP2245033B1 (de) 2011-08-31
WO2009106441A1 (en) 2009-09-03
JP5368484B2 (ja) 2013-12-18
US8008298B2 (en) 2011-08-30
CA2713324A1 (en) 2009-09-03
ES2372908T3 (es) 2012-01-27
JP2011513261A (ja) 2011-04-28
US20100267666A1 (en) 2010-10-21
CN101952295B (zh) 2013-11-20
CN101952295A (zh) 2011-01-19
EP2245033A1 (de) 2010-11-03

Similar Documents

Publication Publication Date Title
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
ATE522536T1 (de) Pyrrolopyrazin-kinasehemmer
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
MX2010008198A (es) Inhibidores de cinasa de pirrolopirazina.
MX359032B (es) Inhibidores de pirrolopirazina cinasa.
WO2011117145A3 (en) Pyrrolopyrazine kinase inhibitors
MX342310B (es) Compuestos de tiazolopirimidina.
MX343561B (es) Compuestos de imidazolpiridazina.
MX352928B (es) Compuestos de piridazina-amida.
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
MX2012002641A (es) Inhibidores de cinasa janus (jak).
UA109775C2 (xx) N-вмісні гетероарильні похідні як інгібітори jak3-кінази
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
MA32811B1 (fr) Nouveaux composés
EA201100447A1 (ru) Органические соединения
EA201170521A1 (ru) Новые соединения
BR112012023752A2 (pt) derivados de pirrolopirazina e seu uso como inibidores de jak e syk
MX2012002385A (es) Inhibidores macrociclicos de cinasa janus.
CR20110620A (es) Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus
MY150596A (en) Hsp90 inhibitors
CU24097B1 (es) Compuestos piridiloxi-indoles sustituidos como inhibidores del vegf-r2 útiles para el tratamiento de enfermedades proliferativas
EA201590277A1 (ru) Дигидропиридон р1 в качестве ингибиторов фактора xia
MA32319B1 (fr) Derives de triazine utiles comme inhibiteurs de la kinase pi3 et de mtor
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties